Results 181 to 190 of about 385,356 (336)

Surface Reconstruction of Single-Twinned AgPdIr Nanoalloy during the Formate Oxidation and Dehydrogenation Reactions

open access: yesACS Omega
Quan Tang   +8 more
doaj   +1 more source

Expanding Hereditary Spastic Paraplegias Limits: Biallelic SPAST Variants in Cerebral Palsy Mimics

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Hereditary spastic paraplegias (HSP) are rare neurodegenerative disorders marked by spasticity and lower limb weakness. The most common type, SPG4, is usually autosomal dominant and caused by SPAST gene variants, typically presenting as pure HSP.
Gregorio A. Nolasco   +18 more
wiley   +1 more source

Scintillating and Photoluminescent Ratiometric and Visual Luminescence Thermometry Based on the Ce<sup>3+</sup>-Doped Eutectic Structures. [PDF]

open access: yesACS Appl Mater Interfaces
Bartosiewicz K   +13 more
europepmc   +1 more source

Cellular instabilities in directional solidification

open access: green, 1986
S. de Cheveigné   +5 more
openalex   +2 more sources

Amyotrophic Lateral Sclerosis Prevalence Projection in 2040: A Less Rare Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To project ALS prevalence across multiple countries through 2040, accounting for both population aging and increased survival. Methods Data from the Piemonte and Valle d'Aosta ALS register (PARALS) was used to estimate the trends in incidence and prevalence from 2005 to 2019. Survival trends over this period were also assessed.
Rosario Vasta   +18 more
wiley   +1 more source

Nonequilibrium chemical short-range order in metallic alloys. [PDF]

open access: yesNat Commun
Islam M, Sheriff K, Cao Y, Freitas R.
europepmc   +1 more source

Plasma Proteomic Signatures for Alzheimer's Disease: Comparable Accuracy to ATN Biomarkers and Cross‐Platform Validation

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy